Bavarian Nordic Nominates Peter Kürstein for Election to the Board
(Thomson Reuters ONE) -
KVISTGAARD, Denmark, April 10, 2012 - Bavarian Nordic A/S (OMX: BAVA) -
Following the notice convening the ordinary general meeting, published on 21
March 2012, the board of directors of Bavarian Nordic hereby announces the
nomination of a new candidate for election at the general meeting on Monday, 16
April 2012.
The candidate is Peter Kürstein, who is President of Radiometer Medical ApS. He
has held managerial positions in Radiometer for many years, the latter eight as
President of the company. He has long experience from the boards of larger
Danish industrial companies. Peter Kürstein holds an MBA from Harvard Business
School in Boston, USA. He is a Danish national and born in 1956.
Peter Kürstein is vice chairman of the board of FOSS A/S and member of the board
of Radiometer Medical ApS. Furthermore he is chairman of the Danish-American
Business Forum and the Committee of Healthcare under the Confederation of Danish
Industries.
Peter Kürstein will replace Erling Johansen in the board, who upon his own
request, has chosen not to be nominated for re-election.
Thus, the candidates for election at the ordinary general meeting are Asger
Aamund, Claus Bræstrup, Gerard van Odijk, Anders Gersel Pedersen, Erik G. Hansen
and Peter Kürstein.
Asger Aamund
Chairman of the Board
Contact
Asger Aamund. Phone +45 40 78 19 11
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC(®), a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC(®) has been tested
in nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE(®), a third-generation smallpox vaccine candidate that is being
developed and supplied for emergency use to the U.S. Strategic National
Stockpile under a contract with the U.S. Government. For more information, visit
www.bavarian-nordic.com
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201205uk:
http://hugin.info/100065/R/1600974/505426.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1600974]
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2012 - 08:02 Uhr
Sprache: Deutsch
News-ID 133148
Anzahl Zeichen: 3980
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Nominates Peter Kürstein for Election to the Board"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
